Joseph C. Papa

Papa received a bachelor's degree in pharmacy from the University of Connecticut in 1978,{{cite web |date=2024 |title=Past Award Winners |url=https://pharmacy.uconn.edu/past-award-winners/ |access-date=June 13, 2024 |website=www.pharmacy.uconn.edu}} and an MBA degree in marketing and finance from Northwestern University's Kellogg Graduate School of Management in 1983.{{cite news |author= |date=June 13, 2023 |title=The Top 50 Healthcare Technology CEOs of 2023 |url=https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2023/ |access-date=June 12, 2024 |work=The Healthcare Technology Report}}{{cite web |date=2024 |title=Joseph Papa, '83 |url=https://www.kellogg.northwestern.edu/news_articles/profiles/alumni/joseph-papa.aspx |access-date=June 13, 2024 |website=www.kellogg.northwestern.edu}}

Papa has been chairman and CEO of Bausch & Lomb since its IPO in May 2022.{{Cite news |date=2022-05-06 |title=Bausch + Lomb Up in Debut After Below-Range $630 Million IPO |language=en |work=Bloomberg.com |url=https://www.bloomberg.com/news/articles/2022-05-06/bausch-lomb-up-in-debut-after-below-range-630-million-ipo |access-date=2022-06-24}} He was previously chairman and CEO of Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.), having succeeded J. Michael Pearson in those roles in May 2016.{{Cite web |last=Gara |first=Antoine |title=Former Perrigo CEO Joe Papa Will Replace Michael Pearson At Valeant Pharmaceuticals |url=https://www.forbes.com/sites/antoinegara/2016/04/25/former-perrigo-ceo-joe-papa-will-replace-michael-pearson-at-valeant-pharmaceuticals/ |access-date=2022-06-24 |website=Forbes |language=en}} Papa resigned as CEO of Bausch Health upon becoming chairman and CEO of Bausch & Lomb in May 2022, but retained his position as chairman of Bausch Health until his resignation on June 23, 2022.{{Cite web |last=Kilgore |first=Tomi |title=Bausch Health's Joe Papa resigns from board, John Paulson named chairperson |url=https://www.marketwatch.com/story/bausch-healths-joe-papa-resigns-from-board-john-paulson-named-chairperson-2022-06-24 |access-date=2022-06-24 |website=MarketWatch |language=EN-US}} Prior to joining Valeant, Papa was the chairman and CEO of Perrigo, an American manufacturer of private label over-the-counter pharmaceuticals, from 2006 to 2016.{{cite web|author= |url=https://www.businessinsider.com/valeant-new-ceo-pay-package-2016-4?r=US&IR=T |title=Valeant new ceo pay package - Business Insider |website=Uk.businessinsider.com |date=March 31, 2016 |access-date=April 29, 2016}} From December 2004 to October 2006, Papa was chairman and CEO of the pharmaceutical and technologies services of Cardinal Health, an Ohio health care services company. From 2001 to 2004, he was president and chief operating officer of Watson Pharmaceuticals, Inc. He has also worked at Novartis and Pharmacia/Searle, where he launched the medications Celebrex, Diovan, and Lotrel.{{cite web|title=Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals|url=http://ir.valeant.com/news-releases/2016/04-25-2016-133930304|website=ir.valeant.com/|publisher=Valeant Pharmaceuticals International, Inc.|accessdate=May 10, 2016|language=English|date=April 25, 2016}}

In 2014, he was ranked 47th on Harvard Business Review's "Best Performing CEOs in the World".{{Cite news|last=Staff|first=Harvard Business Review|url=https://hbr.org/2014/11/the-best-performing-ceos-in-the-world|title=The Best-Performing CEOs in the World|date=2014-11-01|work=Harvard Business Review|access-date=2020-02-26|issue=November 2014|issn=0017-8012}}

In March 2017, it was reported that Papa received US$62.7 million in total compensation for his first eight months of work in 2016.{{cite web|url=http://business.financialpost.com/investing/valeant-paid-ceo-joe-papa-us63m-in-compensation-for-eight-months-of-work-last-year-but-mostly-in-company-stock |title=Valeant paid CEO Joe Papa US$63M in compensation for eight months of work — but mostly in company stock | Financial Post |publisher=Business.financialpost.com |date= |accessdate=June 19, 2017}}{{Cite web|url=https://montrealgazette.com/business/new-valeant-pharmaceuticals-ceo-got-us63-million-in-compensation|title=New Valeant Pharmaceuticals CEO compensated US$63-million in 2016|last=|first=|date=|website=|access-date=}}

In March 2020, Bausch Health reported that Papa's gross income for 2019 rose to $17.1 million from $14.7 million in 2018.{{Cite web|last=|first=|date=17 March 2020|title=BRIEF-Bausch Health Reports CEO Joseph C. Papa's 2019 Total Compensation Was $17.1 Mln|url=https://www.reuters.com/article/brief-bausch-health-reports-ceo-joseph-c-idUSFWN2B91XQ|access-date=9 June 2020|website=Reuters}}

In May 2022, Bausch Health reported that Papa’s gross income increased again to $22.9 million, as compared to the $44,617 median compensation of all other Bausch Health employees, reflecting a pay ratio of 513:1.{{Cite web |title=DEF 14A |url=https://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm |access-date=2022-06-24 |website=www.sec.gov}}

As of May 2015, Papa had been married for 32 years.{{cite web|url=https://www.mlive.com/business/west-michigan/index.ssf/2015/11/perrigo_ceo_thanks_shareholder.html|title=Perrigo's Joe Papa says shareholders, Allegan truly different|author=|date=November 14, 2015|website=mlive.com|accessdate=October 3, 2018}}

{{Reflist}}

{{Authority control}}

{{DEFAULTSORT:Papa, Joseph C}}

Category:Living people

Category:American chief executives

Category:University of Connecticut alumni

Category:Kellogg School of Management alumni

Category:1955 births